Laboratorios Farmacéuticos ROVI, S.A .
Spain · ES0157261019 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?To watch
- Revenue −7.9% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Good
- It earned 24% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Good
- Equity is 70% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | €649M | €818M | €830M | €764M |
| Operating profit | €181M | €256M | €220M | €180M |
| Net profit to shareholders | €153M | €200M | €170M | €137M |
| Earnings per share | €2.76 | €3.73 | €3.20 | €2.67 |
| Dividend per share | n/a | €0.96 | n/a | €1.10 |
| Cash from operations | €149M | €238M | €113M | €138M |
| Capital spending | €40M | €51M | €54M | €59M |
| Cash | €99M | €125M | €25M | €27M |
| Total assets | €733M | €879M | €800M | €832M |
| Equity | €471M | €521M | €543M | €582M |
What they do
In the company's own words, from the annual report.
La actividad de la Sociedad se concentra en la venta de productos propios farmacéuticos, así como en la distribución de otros productos para los cuales es licenciataria de otros laboratorios por períodos determinados, de acuerdo con las condiciones establecidas en los contratos suscritos con los mismos, y en la prestación de servicios de fabricación a terceros.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.